2 citations
,
November 2022 in “Skin research and technology” 5% topical minoxidil improves hair density and quality in monilethrix patients.
2 citations
,
January 2025 in “JAAD Case Reports” Topical metformin may improve hair regrowth in CCCA when added to standard treatments.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
January 2023 in “Journal of The American Society of Nephrology” Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
August 2025 in “Journal of the American Academy of Dermatology” 7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
2 citations
,
November 2024 in “In Silico Pharmacology”
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
3 citations
,
January 2021 in “Molecular genetics & genomic medicine” The study found two new mutations in a Chinese patient with severe biotinidase deficiency.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
Baricitinib effectively regrows hair in severe alopecia areata cases.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
17 citations
,
February 1989 in “Fertility and sterility” Cimetidine did not reduce hair growth in women with hirsutism.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
39 citations
,
October 2012 in “Familial cancer” New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.
March 2026 in “American Journal of Clinical Dermatology”